4.5 Article

Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE

期刊

EUROPEAN JOURNAL OF HUMAN GENETICS
卷 15, 期 8, 页码 823-830

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.ejhg.5201827

关键词

systemic lupus erythematosus; human leukocyte antigen; association study

资金

  1. NCRR NIH HHS [RR024013, 5 M01 RR00079] Funding Source: Medline
  2. NIAID NIH HHS [AI32584, AI24717] Funding Source: Medline
  3. NIAMS NIH HHS [P60 AR053308, AR42460, AR12253, AR048940, AR048094] Funding Source: Medline

向作者/读者索取更多资源

The human leukocyte antigen ( HLA) Class II antigen presentation alleles DR and DQ are associated with susceptibility to systemic lupus erythematosus ( SLE) and the production of lupus-related autoantibodies. Here, we explore the effect of different combinations of Class II risk haplotypes in a large, multi-center collection of 780 SLE families. Haplotypes bearing the DRB1*1501/DQB1*0602 (DR2) and DRB1*0301/DQB1* 0201 (DR3) alleles were present in nearly two-thirds of SLE cases and were significantly associated with disease susceptibility in both family-based and case-control study designs. DR3-containing haplotypes conferred higher risk for disease than DR2, and individual homozygous for DR3 or compound heterozygous for DR3 and DR2 showed the highest risk profile. DR2 haplotypes were also found to be associated with antibodies to the nuclear antigen Sm, and, as previously observed, DR3 genotypes were associated with Ro and La autoantibodies. Interestingly, SLE cases and unaffected family members who were DR2/DR3 compound heterozygotes showed particularly strong risk of developing antibodies to Ro, and were enriched for La and Sm. These data provide convincing evidence that particular combinations of HLA Class II DR2 and DR3 haplotypes are key determinants of autoantibody production and disease susceptibility in human SLE.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据